强生-话题@MedSci

#强生#

169篇内容 | 5288人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1271706, encodeId=124712e1706d9, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生Zejula获美国FDA突破性药物资格中国大陆已进入优先审查！, objectType=article, longId=180817, objectId=185018081e44, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=185018081e44, replyNumber=0, likeNumber=69, createdTime=2019-10-11, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=185018081e44, moduleTitle=强生Zejula获美国FDA突破性药物资格中国大陆已进入优先审查！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=185018081e44)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271705, encodeId=82db12e1705b4, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, objectType=article, longId=180571, objectId=711e1805e121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=711e1805e121, replyNumber=0, likeNumber=84, createdTime=2019-10-07, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=711e1805e121, moduleTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=711e1805e121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271704, encodeId=5a0d12e1704f5, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生的雄激素受体抑制剂Erleada获得FDA批准，治疗转移性去势敏感性前列腺癌, objectType=article, longId=179672, objectId=33491e967221, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33491e967221, replyNumber=0, likeNumber=79, createdTime=2019-09-20, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33491e967221, moduleTitle=强生的雄激素受体抑制剂Erleada获得FDA批准，治疗转移性去势敏感性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33491e967221)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271703, encodeId=e4a112e170348, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症, objectType=article, longId=177713, objectId=d3701e7713cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3701e7713cf, replyNumber=0, likeNumber=75, createdTime=2019-08-17, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3701e7713cf, moduleTitle=强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3701e7713cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271702, encodeId=dc2712e1702a4, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=FDA加速批准了强生的SIRTURO（bedaquiline）作为联合治疗的一部分，用于肺部多重耐药结核病感染的青少年, objectType=article, longId=177571, objectId=43a21e757124, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43a21e757124, replyNumber=0, likeNumber=78, createdTime=2019-08-15, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43a21e757124, moduleTitle=FDA加速批准了强生的SIRTURO（bedaquiline）作为联合治疗的一部分，用于肺部多重耐药结核病感染的青少年, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43a21e757124)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271701, encodeId=610b12e1701fd, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生向FDA提交申请寻求批准其抗CD38单抗DARZALEX皮下制剂治疗多发性骨髓瘤, objectType=article, longId=175459, objectId=e3f31e5459bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3f31e5459bb, replyNumber=0, likeNumber=81, createdTime=2019-07-16, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3f31e5459bb, moduleTitle=强生向FDA提交申请寻求批准其抗CD38单抗DARZALEX皮下制剂治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3f31e5459bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271700, encodeId=590e12e1700c2, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=2019年国际血栓和止血学会：强生宣布抗凝剂Xarelto在儿科静脉血栓栓塞III期临床取得成功, objectType=article, longId=175120, objectId=15c11e51207f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15c11e51207f, replyNumber=0, likeNumber=64, createdTime=2019-07-12, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15c11e51207f, moduleTitle=2019年国际血栓和止血学会：强生宣布抗凝剂Xarelto在儿科静脉血栓栓塞III期临床取得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15c11e51207f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271699, encodeId=25bd12e169979, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生上榜《麻省理工科技评论》2019“50家聪明的公司”, objectType=article, longId=174661, objectId=f9671e466109, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9671e466109, replyNumber=0, likeNumber=77, createdTime=2019-07-03, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9671e466109, moduleTitle=强生上榜《麻省理工科技评论》2019“50家聪明的公司”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9671e466109)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271698, encodeId=ea6d12e16987f, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生的HIV预防性疫苗Imbokodo已经完成临床受试者的招募, objectType=article, longId=167493, objectId=435a16e49305, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=435a16e49305, replyNumber=0, likeNumber=75, createdTime=2019-06-03, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=435a16e49305, moduleTitle=强生的HIV预防性疫苗Imbokodo已经完成临床受试者的招募, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=435a16e49305)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271697, encodeId=de4e12e1697b8, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生医疗傲胸女王盛典在博鳌举行, objectType=article, longId=166576, objectId=08cc1665e646, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08cc1665e646, replyNumber=0, likeNumber=73, createdTime=2019-05-23, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08cc1665e646, moduleTitle=强生医疗傲胸女王盛典在博鳌举行, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=08cc1665e646)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271696, encodeId=0a1c12e1696df, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生医疗：人工智能加速医疗创新, objectType=article, longId=166528, objectId=138d166528e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=138d166528e4, replyNumber=0, likeNumber=78, createdTime=2019-05-22, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=138d166528e4, moduleTitle=强生医疗：人工智能加速医疗创新, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=138d166528e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271695, encodeId=bea012e16950f, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生的膀胱癌靶向治疗药物Balversa在美国获批, objectType=article, longId=164357, objectId=a0b416435e0c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0b416435e0c, replyNumber=0, likeNumber=70, createdTime=2019-04-17, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0b416435e0c, moduleTitle=强生的膀胱癌靶向治疗药物Balversa在美国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0b416435e0c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271694, encodeId=1ada12e169452, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, objectType=article, longId=164340, objectId=bc7c1643405d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc7c1643405d, replyNumber=0, likeNumber=100, createdTime=2019-04-17, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc7c1643405d, moduleTitle=III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc7c1643405d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271693, encodeId=5f8e12e169392, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生CAR-T疗法JNJ-68284528获得了EMA的PRIME认证, objectType=article, longId=163718, objectId=c32e163e1867, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c32e163e1867, replyNumber=0, likeNumber=69, createdTime=2019-04-07, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c32e163e1867, moduleTitle=强生CAR-T疗法JNJ-68284528获得了EMA的PRIME认证, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c32e163e1867)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271692, encodeId=718312e16920e, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=两项3期临床试验证实，葛兰素史克和强生的长效艾滋病疗法可以控制艾滋病毒, objectType=article, longId=161939, objectId=7e591619392f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e591619392f, replyNumber=0, likeNumber=88, createdTime=2019-03-10, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e591619392f, moduleTitle=两项3期临床试验证实，葛兰素史克和强生的长效艾滋病疗法可以控制艾滋病毒, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e591619392f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271691, encodeId=a30312e1691a1, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生宣布在华启动女性科学家专项奖学金项目, objectType=article, longId=161880, objectId=8760161880a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8760161880a0, replyNumber=0, likeNumber=72, createdTime=2019-03-09, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8760161880a0, moduleTitle=强生宣布在华启动女性科学家专项奖学金项目, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8760161880a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271690, encodeId=877012e1690de, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生的Spravato获FDA批准用于治疗抵抗性抑郁症, objectType=article, longId=161783, objectId=f906161e83cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f906161e83cd, replyNumber=0, likeNumber=74, createdTime=2019-03-08, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f906161e83cd, moduleTitle=强生的Spravato获FDA批准用于治疗抵抗性抑郁症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f906161e83cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271689, encodeId=cd9112e168976, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=第14届欧洲克罗恩病和结肠炎组织（ECCO）大会：强生公司将展示多项研究成果, objectType=article, longId=161336, objectId=efde161336db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=efde161336db, replyNumber=0, likeNumber=88, createdTime=2019-03-01, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=efde161336db, moduleTitle=第14届欧洲克罗恩病和结肠炎组织（ECCO）大会：强生公司将展示多项研究成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=efde161336db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271688, encodeId=184512e168807, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案, objectType=article, longId=159161, objectId=a1f815916100, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1f815916100, replyNumber=0, likeNumber=65, createdTime=2019-01-31, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1f815916100, moduleTitle=FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1f815916100)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271687, encodeId=6fbc12e168707, content=<a href='/topic/show?id=2c6c501e578' target=_blank style='color:#2F92EE;'>#强生#</a>, objectTitle=强生公司寻求在欧洲扩大伊布替尼的适应症, objectType=article, longId=153631, objectId=eeed153631ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eeed153631ca, replyNumber=0, likeNumber=105, createdTime=2018-11-17, rootId=0, userName=liuyong2980, userId=de89102, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eeed153631ca, moduleTitle=强生公司寻求在欧洲扩大伊布替尼的适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eeed153631ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

强生

2020-05-29

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生Zejula获美国FDA突破性药物资格中国大陆已进入优先审查！

2019-10-11

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率

2019-10-07

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生的雄激素受体抑制剂Erleada获得FDA批准，治疗转移性去势敏感性前列腺癌

2019-09-20

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症

2019-08-17

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

FDA加速批准了强生的SIRTURO（bedaquiline）作为联合治疗的一部分，用于肺部多重耐药结核病感染的青少年

2019-08-15

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生向FDA提交申请寻求批准其抗CD38单抗DARZALEX皮下制剂治疗多发性骨髓瘤

2019-07-16

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

2019年国际血栓和止血学会：强生宣布抗凝剂Xarelto在儿科静脉血栓栓塞III期临床取得成功

2019-07-12

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生上榜《麻省理工科技评论》2019“50家聪明的公司”

2019-07-03

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生的HIV预防性疫苗Imbokodo已经完成临床受试者的招募

2019-06-03

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生医疗傲胸女王盛典在博鳌举行

2019-05-23

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生医疗：人工智能加速医疗创新

2019-05-22

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生的膀胱癌靶向治疗药物Balversa在美国获批

2019-04-17

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

III期临床试验证实，强生的SGLT2抑制剂Invokana可降低糖尿病患者患糖尿病肾病的风险

2019-04-17

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生CAR-T疗法JNJ-68284528获得了EMA的PRIME认证

2019-04-07

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

两项3期临床试验证实，葛兰素史克和强生的长效艾滋病疗法可以控制艾滋病毒

2019-03-10

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生宣布在华启动女性科学家专项奖学金项目

2019-03-09

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生的Spravato获FDA批准用于治疗抵抗性抑郁症

2019-03-08

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

第14届欧洲克罗恩病和结肠炎组织（ECCO）大会：强生公司将展示多项研究成果

2019-03-01

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案

2019-01-31

liuyong2980 (审核中...)

前往app查看评论内容

#强生#

强生公司寻求在欧洲扩大伊布替尼的适应症

2018-11-17

科室
- - 订阅+
  - 更多科室
工具
服务